OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION PHASE TO EVALUATE THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF RO5509554 AND MPDL3280A ADMINISTERED IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Atezolizumab (Primary) ; Emactuzumab (Primary)
- Indications Bladder cancer; Breast cancer; Gastric cancer; Ovarian cancer; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Roche
- 22 Jan 2018 Planned End Date changed from 21 Sep 2018 to 1 Nov 2018.
- 22 Jan 2018 Planned primary completion date changed from 21 Sep 2018 to 1 Nov 2018.
- 13 Apr 2017 Planned number of patients changed from 162 to 310.